Business Offer

2017/07/31

Afghanistan

This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-GD2 IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The fusion protein retains its ability to activate IL2 responsive cells through the IL2 receptor and retains its ability to bind to GD2-positive tumor cells and to deliver IL2 to their surface. This immunocytokine was designed for treating neuroblastomas, medulloblastomas, astrocytomas, melanomas, small-cell lung cancer, osteosarcomas and other soft tissue sarcomas.

This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-GD2 IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The fusion protein retains its ability to activate IL2 responsive cells through the IL2 receptor and retains its ability to bind to GD2-positive tumor cells and to deliver IL2 to their surface. This immunocytokine was designed for treating neuroblastomas, medulloblastomas, astrocytomas, melanomas, small-cell lung cancer, osteosarcomas and other soft tissue sarcomas.. http://www.creativebiolabs.net/Anti-GD2-Immunocytokine-IgG-hu14-18-IL2-22495.htm

[RequestAdvantages]

[RequestComments]

382

Creative Biolabs